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11 ABSTRACT: A series of 2-pyrazolyl quinolones has been designed and synthesized in 5−7 steps to optimize for both in vitro
12 antimalarial potency and various in vitro drug metabolism and pharmacokinetics (DMPK) features. The most potent
13 compounds display no cross-resistance with multidrug resistant parasite strains (W2) compared to drug sensitive strains (3D7),
14 with IC50 (concentration of drug required to achieve half maximal growth suppression) values in the range of 15−33 nM.
15 Furthermore, members of the series retain moderate activity against the atovaquone-resistant parasite isolate (TM90C2B). The
16 described 2-pyrazoyl series displays improved DMPK properties, including improved aqueous solubility compared to previously
17 reported quinolone series and acceptable safety margin through in vitro cytotoxicity assessment. The 2-pyrazolyl quinolones are
18 believed to bind to the ubiquinone-reducing Qi site of the parasite bc1 complex, which is supported by crystallographic studies of
19 bovine cytochrome bc1 complex.
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21Malaria was responsible for nearly 216 million cases and an22 estimated 445,000 deaths in 2016.1 Approximately half of
23 the global population is at risk of infection, particularly in the
24 tropical and subtropical regions where malaria is widespread.
25 Malaria is a disease caused by the parasite of the genus
26 Plasmodium and is transmitted to people through the bites of
27 infected female Anophelesmosquitoes. Plasmodium falciparum is
28 themost prevalent and lethal species of the parasite to human and
29 has developed resistance to most of the classical antimalarials.2,3
30 Thequinolone scaﬀold is present in several antibiotics, and this
31 chemotype possesses a wide range of biological activities
32 including anticancer, anti-HIV, and antiviral.4−7The antimalarial
33 activity of Endochin was ﬁrst identiﬁed in the 1940s,8 and recent
34 publications have highlighted the promising potential antima-
35 larial properties of aryl and alkyl substituted quinolones.9−12
36 Studies by Nilsen and co-workers discovered the quinolone-3-
37 diaryl ethers ELQ-300 and P4Q-391, which have excellent
38 proﬁles and selectively inhibit Plasmodium cytochrome bc1
39 complex.13 Our group14 and others15 have focused on 2-aryl
40quinolones, and we have shown that representative 2-aryl
41quinolones (1) can inhibit two mitochondrial enzymes in the
42electron transport chain, the cytochrome bc1 complex and the
43recently identiﬁed PfNDH2 (Type II NADH:ubiquinone
44oxidoreductase).16,17 This inhibition results in the collapse of
45the mitochondrial membrane potential, the inhibition of de novo
46pyrimidine biosynthesis, and ultimately the death of the
47parasite.18
48Previously compound 1 was identiﬁed by us as one of the lead
49compounds with good antimalarial activity in a drug discovery
50 f1program14 (Figure 1). While compound 1 demonstrated good
51antimalarial activities against various strains of P. falciparum, it
52required further optimization of its physiochemical properties,
53especially lipophilicity (ClogP) and aqueous solubility. In this
54Letter we describe the further optimization and the synthesis of a
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55 series of 2-pyrazolyl quinolone with the aim of reducing ClogP
56 and improving the aqueous solubility while maintaining/
57 improving the antimalarial activity. It has been well documented
58 that pyrazole is a bioisostere for benzene ring and can improve
59 physiochemical properties (i.e., aqueous solubility) by reducing
60 CLogP.19 This strategy was applied to compound 1 by replacing
61 the C-ring with a pyrazolyl ring. Diﬀerent substituents on other
62 parts of themolecule such as A-ring, B-ring, andD-ring were also
63 explored. In addition to medicinal chemistry optimization, we
64 were also interested in probing the eﬀect of chemical substitution
65 on bc1 (Qi) site binding by comparing our previously published
66 bc1 enzyme−inhibitor complexes with lead pyrazoles prepared in
67 this work.
68 The 2-pyrazolyl quinolone analogues were prepared by three
69 diﬀerent synthetic routes. The synthesis of quinolones 4a−h is
s1 70 depicted in Scheme 1. 2-Bromo-4-chloroquinoline 2, synthe-
71 sized from oxidation of corresponding 4-chloroquinoline
72 followed by bromination, was coupled with readily available
73 pyrazole boronic acid pinacol ester, giving the quinoline 3 in 38−
74 93% yields. Upon hydrolysis using acetic acid or formic acid,
75 quinoline 3 provided quinolones 4a−h in excellent yields. Some
76 selected 3H-quinolones were further chlorinated by sodium
77 dichloroisocyanurate to give the 3-Cl analogue 5a−c in 56−72%
78 yields.
79 The synthesis of quinolones 11a−j was accomplished in 3−6
80 steps from commercially available startingmaterials according to
s2 81 the syntheticmethodology showed in Scheme 2.Oxazoline 7was
82 synthesized from the corresponding isatoic anhydride 6 in 60−
83 75%yields. Substituted pyrazole9, synthesized fromcorrespond-
84 ing iodopyrazole 8 and benzyl bromide in excellent yield (see
85 Supporting Information), was converted to ketone20 10 in 26−
86 55% yields. Cyclization of oxazoline 7 with ketone 10 in the
87presence of catalytic triﬂuoromethanesulfonic acid aﬀorded the
88desired quinolones 11a−j in 42−84% yields.
89Investigations also focused on the possibility of formulating
90the series as salts and improving the solubility by extending the
91side chain and introducing the morpholine group at the terminal
92as illustrated by 13a and 13b. The synthesis of the extended side
93 s3chain quinolone13a and13bwas shown in Scheme3.Quinolone
9412 (see Supporting Information) was coupled with the
95corresponding boronic acid pinacol ester to provide quinolone
9613a and 13b.
97In vitro antimalarial activity of the quinolone analogues was
98assessed against the 3D7 strain (chloroquine sensitive) of
99 t1Plasmodium falciparum (Table 1). Several analogues exhibit
100improved antimalarial activity compared with the original lead 1.
101As observed from previous work, a p-OCF3 substituent on theD-
102ring in the 2-pyrazolyl series provides better antimalarial activity
103than p-F. The terminal phenyl ring is more favorable than a
104pyridinyl or morpholine ring. Longer side chains, as seen in 11j,
10513a, and 13b, results in a signiﬁcant loss in antimalarial activity. A
106clear trend is seen in the nature of the A-ring substituent X. In
107general, the presence of F, Cl, and OMe on the A-ring is well
108tolerated and often improves the activity as shown when
109comparing 4e (100 nM), 11c (33 nM), 11g (80 nM), and 11h
110(50 nM). A small electron withdrawing substituent on the 6-
111position of quinolone ismore favorable (see11d and 11e).While
112F and Cl at the 7-position of quinolone exhibit potent activity, 7-
113CF3 is less tolerated and a 8-fold drop in activity is observed.
114Among the substituents on the A-ring, 7-OMe enhances the
115activity greatly. The position of the pyrazolyl ring that links to the
116quinolone core also eﬀects the activity. When the 3-position of
Figure 1. Initial lead 1 and its antimalarial activities and physiochemical
properties.
Scheme 1. General Route 1 for Synthesis of Pyrazole
Quinolonesa
aConditions and reagents: (a) pyrazole boronic acid pinacol ester, 10
mol % PdCl2(dppf), K2CO3·1.5H2O, dioxane, reﬂux, 24 h; (b) AcOH,
H2O, 120 °C, 24−48 h or HCl(aq), dioxane, reﬂux, 48 h or
HCOOH/H2O, DMF, 140 °C, 4 h; (c) sodium dichloroisocyanurate,
MeOH, NaOH(aq), r.t., o/n.
Scheme 2. General Route 2 for Synthesis of Pyrazole
Quinolonesa
aConditions and reagents: (a) 2-amino-2-methyl-propanol, ZnCl2,
PhCl, 135 °C, 24 h; (b) corresponding benzyl bromide, K2CO3,
acetone, reﬂux, 3 h; (c) Pd2(dba)3, dppp, pyrrolidine, 4 Å M.S., DMF,
110 °C, 6 h; (d) CF3SO3H, n-BuOH, N2, 130 °C, 24 h.
Scheme 3. General Route 3 for Synthesis of Pyrzaole
Quinolones with Extended Side-Chainsa
aConditions and reagents: (a) 5 mol % PdCl2(dppf), K2CO3, H2O/
dioxane, 100 °C, 5 h.
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117 pyrazolyl ring is linked to the quinolone core (4h, 5c, and 11i)
118 (instead of the 4-position), there is a reduction in potency.
119 Looking into the substituents at the 3-position of the quinolone,
120 most of substituents, except isopropyl group, are well-tolerated.
121 In contrast to previous SAR studies, 3-chloro analogues are less
122 potent than the 3-Me analogue (as seen in 5b and 11c), which is
123 the most active in this series.
124 A selection of compounds was tested against the chloroquine
125 resistant strain of P. falciparum, W2, and atovaquone resistant
126 TM90C2B containing the Y268S mutation in the quinol
127 oxidation Qo site of the parasite mitochondrial cytochrome bc1
t2 128 complex21−23 (Table 2). The SAR trends observed from the 3D7
129 data are similar to the W2 data with the presence of a 7-methoxy
130 (11c) enhancing activity when compared to unsubstituted
131 analogue (4e). Interestingly, unlike the activity data against 3D7
132 strain, the presence of 3-Cl in the quinolone core enhances
133 activity compared with 3-methylation. In a conﬁrmatory study
134 that assessed antimalarial potency against the transgenic P.
135 falciparum TX13 strain,24 expressing yeast dihydroorotate
136 dehydrogenase,25 5b showed no inhibition at≤1000 nM, further
137 supporting that the series is targeting the respiratory chain of the
138parasite mitochondrion. To determine if the antimalarial activity
139is a result of on-target plasmodial bc1 inhibition, the enzymatic
140activity was determined by monitoring cytochrome c reduction
Table 1. In Vitro Antimalarial Activities of Quinolones versus the 3D7 Strain+ of Plasmodium falciparuma
a50% inhibitory concentration in vitro against P. falciparum chloroquine-sensitive (3D7) lines.
Table 2. In Vitro Antimalarial Activities of Selected
Quinolones versus W2 and TM90C2B and PfNDH2 Enzyme
Inhibition Dataa
compound IC50W2 (nM) IC50 TM90C2B (nM) IC50PfNDH2 (nM)
chloroquine 12.3 14.5 NDb
atovaquone 0.3 9908 10,000
1 26 122 20
4e 33 ND 837
5a 14 ND ND
5b 11 110 ND
11c 15 500 1,000
11i 49 300 68
a50% inhibitory concentration in vitro against P. falciparum
chloroquine-resistant W2 strain (Indochina), Atovaquone resistant
TM90C2B strain, and PfNDH2 enzyme inhibition data.24 bND, not
determined.
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141 using decylubiquinol as electron donor as previously reported.26
142 This enzymatic study conﬁrmed 11c as a potent Pf bc1 inhibitor
143 with an IC50 of 0.75 nM (Figure S1). However, it is noteworthy
144 that, although relative to atovaquone, some of the selected
145 compounds in this series are active against the TM90C2B strain,
146 and reduced potency is seen compared to 3D7 and W2. A
147 possible explanation for this observation could be that for this
148 series, there is a contributing element of Qo site inhibition; it has
149 beennotedbyRiscoe and co-workers thatminormodiﬁcations to
150 the quinolone core of a series of related endochin quinolone
151 analogues can subtly aﬀect bothPf bc1Qo/Qi sites binding.
27This
152 observation may well explain in part the reduced potency of 11c
153 versus the Qo site mutated TM90C2B strain.
154 One of the major aims in this lead optimization process was to
155 improve the physiochemical properties of compound 1,
156 especially its aqueous solubility. Aqueous solubility of molecules
157 is related to lipophilicity (CLogP) and crystal packing via π-
158 stacking of aromatic ring systems (as reﬂected in the melting
159 point).28 Replacement of the benzene C-ring to a pyrazole ring
160 and incorporating various substitutions at the 3-position of the
161 quinolone can dramatically change both CLogP and melting
162 point of the analogues in this series, and thus improve the
t3 163 aqueous solubility proﬁle (Table 3). Replacement of the benzene
164 C-ring with pyrazole reduced CLogP by between 1.5 to 2 units.
165 Incorporation of a substituent, such asMe or Et, at the 3-position
166 of the quinolone ring likely reduces the planarity of the side-
167 chain, reducing packing, and this reduces the melting point. The
168 most signiﬁcant reduction in melting point came as the result of
169 modiﬁcation of the linkage of the pyrazole heterocycle from a 1,4
170 to 1,3 arrangement. The combination of reduction in both
171 lipophilicity and aggregation via π-stacking of aromatic ring
172 systems resulted in over 10-fold improvement in aqueous
173 solubility for some selected analogues in this series (11c and11i).
174 To further examine the DMPK properties, selected com-
175 pounds in the series have also been screened for metabolic
176 stability and plasma protein binding in vitro (Table S1). From the
177 human microsomal stability and rat hepatocyte stability data, all
178 selected representatives in the 2-pyrazolyl quinolone series had
179 very low clearance and good metabolic stability. Most of the
180 tested compounds, except 5a, had high human plasma protein
181 binding level, but below 99.9% bound, which is comparable with
182 other antimalarial quinolones.
183 To gain insight into the key protein/ligand binding
184 interactions of 2-pyrazole quinolones within a bc1 complex, we
185 cocrystallized bovine heart-derived cytochrome bc1
29 with
186 compound 11c. Clear and deﬁned omit Fo−Fc electron density
f2 187 within the Qi pocket near heme bH (Figure 2A,B) showed
188 unambiguous binding of the quinolones to the Qi site. The
189 carbonyl of quinolone core forms H-bonds with His201 side
190 chain, and the aromatic tail is positioned within the hydrophobic
191region. The planar quinolone ring of 11c makes an aromatic
192stacking with the phenyl ring of Phe220, and its amine points to
193the side chain of Ser35. The aromatic tail is packed in the
194hydrophobic cavity conferred by Ile39 and Ile42.
195As there is no structure of P. falciparum cytochrome bc1, its
196homology model was generated by SWISS-MODEL online
197tool30 based on the primary sequence (Q02768) and the bovine
198cytochrome b (PDB:5OKD) template.ThePfmodelwas aligned
199to the bovine crystal structure to visualize inhibitor interactions
200within thePfQi site (Figure S2). The parasite’sQi binding pocket
201appears to be smaller than bovine, and there could be a steric
202contact of Phe30 (Ser35 in bovine) side chain with the pyrazole
203ring of 11c. The inhibitors had to adopt diﬀerent poses in the Pf
204Qi site becauseof steric clasheswith the calculated proteinmodel.
205To predict possible binding poses in the parasite enzyme, in silico
206docking was performed by SwissDock31 with deﬁned interest
207region ofQi site. The ﬁnal solution for 11cwas determined based
208on the compound pose in bovine crystal structure with the
209highest FullFitness scoring of −858.01 kcal/mol. As the absence
210of 7-methoxy group on the A-ring often reduces antimalarial
211activities, compound 4e, which is the unsubstituted analogue of
21211c, was docked into the Pf Qi site with FullFitness score of
213−854.04 kcal/mol. The molecular docking results are shown in
214 f3Figure 3. Both compounds can form a hydrogen bond with
215His192, but the presence of 7-methoxy group in11c causes a shift
216in binding location away from the 4e position with stronger
217binding explained by π-stacking interaction ofD-ringwith Phe30
218and Phe37 side chains. This observation provides insight as to
219how 7-methoxy quinolone analogues have improved potency
220over other derivatives. Future work will utilize the homology Pf
221bc1 model with the mammalian bovine structures described here
222to guide chemical substitution that enhances parasite potency
223and selectivity further.
224Finally, given thatmembers of this series have thepropensity to
225bind to mammalian bc1, we examined the cytotoxicity proﬁles in
226 t4the Hep G2 cell line (Table 4). From this in vitro toxicity
227assessment, the tested 2-pyrazolyl quinolone analogues showed
228similar or higher IC50 values than the negative control,
229Tamoxifen, which indicate low cytotoxicity for the analogues
230tested. Based on the 3D7 IC50 data, there is a suﬃcient safety
231windows for the tested analogues with 11c expressing the highest
232therapeutic index ratio of 333.
Table 3. CLogP Value, Melting Point, and Aqueous Solubility
at pH 7.4 for Selected 2-Pyrazolyl Quinolones
compound CLogP melting point (°C) solubilitya (μM)
1 5.67 213 0.03
4e 3.71 194 0.1
5a 4.04 256 0.01
11a 4.24 143 0.2
11c 3.70 172 0.3
11i 3.92 64 0.4
aSolubility in pH 7.4 PBS buﬀer.
Figure 2. Cytochrome bc1 Qi site with bound 11c inhibitors. (A) The
omit Fo−Fc map (green) contoured at 3σ level around 11c (teal)
compounds shown as sticks. The cartoon representation of cytochrome
b subunit is shown in blue. The Qi and Qo sites are marked by black
boxes. (B) The 2Fo−Fc electron density map (cyan) contoured at 1σ
level around the inhibitors. Surrounding residues are drawn as blue lines
and hydrogen bonds as black dashed lines.
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233 To conclude, a series of 2-pyrazolyl quinolones with potent
234 antimalarial activity against the 3D7 strain and W2 strain of P.
235 falciparum have been identiﬁed. Representative analogue 11c has
236 improved antimalarial activity, physiochemical, and DMPK
237 properties in comparison to previously reported lead molecules
238 in addition to low cytotoxicity. While the series on a whole have
239 improved solubility compared with previous quinolone deriva-
240 tives, further work is required to ﬁnd quinolone derivatives with
241 solubility in amore desired range (>50μM).Crystallography and
242 homology based modeling of mammalian and parasite bc1
243 complexes have now been produced that may allow rational
244 drug design approaches to be initiated formore selectivePf bc1Qi
245 inhibitors. It is noteworthy that, despite the enzymatic and
246 crystallographic data described above, we cannot rule out that
247 this series of 2-pyrazolyl quinolones may potentially target other
248 components of the electron transport chain of the parasite
249 mitochondrion.
250 Further work also is in progress to investigate the in vivo PK
251 proﬁles and eﬃcacy of this series and to proﬁle the lead
252 compounds for their activity against liver and sexual stage of the
253 parasites.
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